A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Phase 1 Completed 69 enrolled Evelo Biosciences, Inc. Merck Sharp & Dohme LLC · collab SCRI Development Innovations, LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors

Timeline

Start: 2018-12-19
Primary completion: 2021-06-30
Completion: 2021-10-31

Publications

Wang JS, Arrowsmith ER, Beck JT, Friedmann J, Jamal R, McHale D, Gardner H, Chisamore MJ, Ulahannan SV. Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors. Invest New Drugs. 2025 Aug;43(4):894-903. doi: 10.1007/s10637-025-01573-0. Epub 2025 Aug 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EDP1503	Other / unclassified	2 unknown	Oral
Subject	EDP1503	Other / unclassified	4 unknown	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Summary

Timeline

Publications

Drugs

Indications